GALVUS

Reason for request

Clinical Benefit

Insufficient

the Committee considers that the actual benefit of GALVUS as monotherapy in patients whose glycaemic control is inadequate despite diet and physical exercise alone and for whom metformin is not tolerated or is contraindicated is insufficient for reimbursement by National Health Insurance.